Tumor Microenvironment Targeted and Immunotherapies for Brain Cancer

Dear Colleagues,          

Primary and metastastic brain cancers still represent an unmet clinical need with an urgent need for improved therapy options. Paucity in treatment success can in part be attributed to the unique tissue environment of the brain harboring a multitude of highly specialized cell types. Given the presence of the blood–brain barrier, the brain has traditionally been regarded as an immune privileged organ. However, the discovery of a dural lymphatic system and the identification of various myeloid and lymphoid cell types in border-associated regions of the brain changed our view on immunity within the central nervous system. The emerging field of neuro-immunology provides unprecedented opportunities for the development of novel therapeutic avenues that target different immune cell types, aiming at improving immune recognition and destruction of cancer cells or the blockade of tumor-promoting functions of cells of the tumor immune microenvironment in primary and metastastic cancers.

This Special Issue will focus on recent developments in tumor microenvironment-targeted therapies and immunotherapies for primary and metastatic brain cancers and welcomes original articles or reviews highlighting novel therapeutic strategies of inducing anti-cancer immune responses or blocking tumor-promoting functions of brain-resident or recruited immune cell types in CNS tumors.

Dr. Lisa Sevenich
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.